By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cellular analysis technologies company Cyntellect has raised $3 million in financing in an equity, debt, and warrant options sale, according to a filing with the US Securities and Exchange Commission.

Cyntellect’s technologies include in situ, microplate-based cytometry instruments for use in cell-based diagnostics and therapeutics.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.